Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916590&utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_iWkG_DPuj8wVpf3bNDrIywHAGuDk4xowjR7Zmq-xzsWN0hWJd-eAw5kmGPKhvungVmdnDR5T-xfJOBrVSdVPsCoMXJA&_hsmi=431702704&utm_content=431702704&utm_source=hs_email Novo vs. Lilly The two GLP-1 giants have both reported earnings. Novo Nordisk raised its outlook, saying it now anticipates 2026 sales to drop 0% to -6% from last year. (It previously forecasted a 4% to 12% drop.) But investors were disappointed that sales of its Wegovy pill in the second quarter weren't as high as some wanted to see. Novo shares were down about 4% this morning in Copenhagen. Still, Novo executives, on a call with reporters this morning, touted the speedy rollout of the Wegovy pill, even with Eli Lilly's oral drug Foundayo now on the market as well. The Wegovy pill, which launched early this year in the U.S., has since gone on sale in the UAE and U.K., with plans to debut soon in Germany. There have been 5 million prescriptions, and while it took 12 weeks to reach 1 million patients, the most recent million were added in four weeks. Most patients starting on the pill have not previously tried a GLP-1 drug. "We also find people coming to Wegovy pill from competitor products, and limited cannibalization on injectable Wegovy, which is quite encouraging,” Novo CEO Mike Doustdar told reporters. Meanwhile, Lilly shares were up in pre-market trading after the company reported results, including sales of its diabetes and obesity drugs, that outpaced analyst expectations. The company also raised its full-year guidance, with revenue now expected to be $85 billion to $87 billion, up from $82 billion to $85 billion. https://www.statnews.com/2026/05/06/biotech-news-novo-nordisk-wegovy-pill-raises-share-prices/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz--4v9pycNPdWWcwW9wrWX8ZO9Gwvm0PnHr5jD_PAqF6m_e2mrKOrVJPKzf5uybPLGS60ADiESwlgl3e6SlXqcFTugai-g&_hsmi=431702704&utm_content=431702704&utm_source=hs_email